Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Auto-SCT in severe paraproteinemic neuropathy

Bone Marrow Transplantation volume 46, pages 457–459 (2011)Cite this article

Subjects

Paraproteinemic neuropathies (PNs) encompass a heterogenous group of neurological disorders, which may not be clinically distinguishable from chronic inflammatory demyelinating neuropathy (CIDP). They are by definition associated with monoclonal gammopathy or plasma cell dyscrasia. The non-malignant forms have also been termed CIDP with monoclonal gammopathy of undetermined significance (MGUS-CIDP).1 In spite of some experimental evidence,2 a causative role of the paraprotein for the neuropathy has not yet been proven beyond doubt, and the exact pathophysiology in all these disorders has not yet been uncovered.3 Only in a defined subset of patients does a monoclonal IgM kappa paraprotein react specifically with myelin-associated glycoprotein (MAG), and this is likely to be of pathogenic significance.4 Standard treatment options include i.v. Igs, plasmapheresis or immunosuppressive treatment (for example, corticosteroids, azathioprine or CY) and—rarely—immunoselective treatment using monoclonal antibodies (anti-CD20, anti-TNF-alpha and anti-CD52).5 The response to treatment is variable, but most patients can be stabilized or even improved.5 Nevertheless, a group of patients remain refractory to these treatment modalities, including some of those with anti-MAG-associated neuropathy.5 For these cases intensive immunosuppression followed by auto-SCT could be an alternative therapy concept. However, until now only two case reports have been published describing successful ASCT after high-dose melphalan (HD-Mel) followed by amelioration of neurological symptoms.6, 7

Here we report our experience on four patients with severe treatment-refractory acquired PN treated with HD-Mel and ASCT.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 2006; 11: 9–19.

    Article  Google Scholar 

  2. Besinger UA, Toyka KV, Anzil AP, Fateh-Mognadam A, Rouscher R, Heininger K . Myeloma neuropathy: passive transfer from man to mouse. Science 1981; 213: 1027–1030.

    Article  CAS  PubMed  Google Scholar 

  3. Latov N . Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Ann Neurol 1995; 37 (S1): S32–S42.

    Article  PubMed  Google Scholar 

  4. Steck AJ, Stalder AK, Renaud S . Anti-myelin-associated glycoprotein neuropathy. Curr Opin Neurol 2006; 19: 458–563.

    Article  CAS  PubMed  Google Scholar 

  5. Brannagan TH . Current treatments of chronic immune-mediated demyelinating polyneuropathies. Muscle Nerve 2009; 39: 1–16.

    Article  Google Scholar 

  6. Lee YC, Came N, Schwarer A, Day B . Autologous peripheral blood stem cell transplantation for peripheral neuropathy secondary to monoclonal gammopathy of unknown significance. Bone Marrow Transplant 2002; 30: 53–56.

    Article  CAS  PubMed  Google Scholar 

  7. Mahdi-Rogers M, Kazmi M, Ferner R, Hughes RA, Renaud S, Steck AJ et al. Autologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathy. J Peripher Nerv Syst 2009; 14: 118–124.

    Article  PubMed  Google Scholar 

  8. Sommer C, Koch S, Lammens M, Gabreels-Festen A, Stoll G, Toyka KV . Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP. Neurology 2005; 65: 1924–1929.

    Article  CAS  PubMed  Google Scholar 

  9. Hohlfeld R, Toyka KV, Heininger K, Gerhold B . Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of azathioprine. Ann Neurol 1985; 17: 238–242.

    Article  CAS  PubMed  Google Scholar 

  10. Drachman DB, Jones RJ, Brodsky RA . Treatment of refractory myasthenia: ‘rebooting’ with high-dose cyclophosphamide. Ann Neurol 2003; 53: 29–34.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

MST is supported by a grant from the Deutsche Forschungsgemeinschaft (KFO 216). RCB and HE are supported by the Deutsche Jose-Carreras-Leukämie-Stiftung (Nr. DJCLS H 08/02). CS, HW and KVT are supported by grants from the Deutsche Forschungsgemeinschaft and intramural research funds.

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik II, Universitätsklinik Würzburg, Würzburg, Germany

    H D Hummel, J C Rath, R C Bargou, H Einsele & M S Topp

  2. Neurologische Klinik und Poliklinik, Universitätsklinik Würzburg, Würzburg, Germany

    H Wiendl, K V Toyka & C Sommer

  3. Arzt für Neurologie und Psychiatrie, Würzburg, Germany

    W Hetzel

Authors
  1. H D Hummel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J C Rath
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Wiendl
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W Hetzel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R C Bargou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K V Toyka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Sommer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H Einsele
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M S Topp
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H D Hummel.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hummel, H., Rath, J., Wiendl, H. et al. Auto-SCT in severe paraproteinemic neuropathy. Bone Marrow Transplant 46, 457–459 (2011). https://doi.org/10.1038/bmt.2010.124

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.124

This article is cited by

Search

Advanced search

Quick links